Inspire Medical Systems (NYSE:INSP) Stock Rating Upgraded by Zacks Research

Inspire Medical Systems (NYSE:INSP) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Several other brokerages have also issued reports on INSP. Summit Redstone set a $39.00 price target on shares of Inspire Medical Systems in a research note on Friday, May 22nd. JPMorgan Chase & Co. increased their price objective on shares of Inspire Medical Systems from $54.00 to $60.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Wells Fargo & Company decreased their price objective on Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a report on Tuesday, May 5th. Freedom Capital raised Inspire Medical Systems to a “strong-buy” rating in a research report on Tuesday, June 30th. Finally, Truist Financial reiterated a “hold” rating and set a $62.00 target price (up from $54.00) on shares of Inspire Medical Systems in a report on Tuesday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, eleven have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $66.19.

Inspire Medical Systems Stock Up 0.4%

Shares of INSP opened at $57.43 on Monday. The stock has a market capitalization of $1.66 billion, a P/E ratio of 12.43, a P/E/G ratio of 4.34 and a beta of 0.70. Inspire Medical Systems has a twelve month low of $38.91 and a twelve month high of $147.03. The company has a 50 day moving average of $49.98 and a 200-day moving average of $52.92.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. The company had revenue of $200.58 million for the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm’s revenue was down 7.6% compared to the same quarter last year. During the same period last year, the company earned $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, sell-side analysts anticipate that Inspire Medical Systems will post 1.24 earnings per share for the current fiscal year.

Insider Buying and Selling at Inspire Medical Systems

In related news, insider Jason P. Kelly sold 963 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider directly owned 18,985 shares in the company, valued at approximately $1,130,556.75. This trade represents a 4.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.20% of the stock is owned by corporate insiders.

Institutional Trading of Inspire Medical Systems

Several institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of Inspire Medical Systems in the second quarter valued at approximately $211,341,000. Wellington Management Group LLP acquired a new position in shares of Inspire Medical Systems during the 4th quarter worth approximately $203,929,000. Wasatch Advisors LP increased its holdings in shares of Inspire Medical Systems by 7.2% during the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock worth $212,095,000 after acquiring an additional 110,288 shares during the last quarter. Morgan Stanley raised its stake in Inspire Medical Systems by 179.5% in the 4th quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after acquiring an additional 809,121 shares during the period. Finally, Deerfield Management Company L.P. raised its stake in Inspire Medical Systems by 648.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after acquiring an additional 907,694 shares during the period. Institutional investors own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.